相关实验视频
Updated: Jun 8, 2025
04:44
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
216
双极性或精神分裂性谱系障碍患者的益生菌配方:双盲,随机的安慰剂控制试验
Jenny Borkent1, Magdalini Ioannou1,2, Dorien Neijzen3
1Department of Biomedical Sciences, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Schizophrenia bulletin
|November 6, 2024
概括
益生菌有望改善双相情感障碍 (BD) 和精神分裂症谱系障碍 (SSD) 患者的肠道健康,对精神病症状没有显著影响,但对口头记忆有潜在的益处. 这种干预措施是安全的,并且耐受性很好.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
背景情况:
- 双极性障碍 (BD) 和精神分裂谱系障碍 (SSD) 是可能受到微生物组偏差影响的复杂大脑疾病.
- 正在探索益生菌干预措施,以针对这些条件下的肠-大脑轴功能障碍.
研究的目的:
- 调查多菌株益生菌配方 (生态障碍物) 在改善精神和认知症状,肠道透性和胃肠道症状的疗效,在BD或SSD患者.
- 在这个患者群体中评估益生菌补充剂的安全性和耐受性.
主要方法:
- 一个为期3个月的,双盲,随机,安慰剂对照试验,涉及131名患有BD或SSD的患者.
- 参与者接受了益生菌补充剂或安慰剂,以及他们的通常治疗.
- 主要结局包括症状严重程度 (简要精神病学评分表) 和认知功能 (精神分裂症认知简要评估).
主要成果:
- 没有观察到整体精神症状的显著改善.
- 观察到口头记忆的边缘显著改善 (调整后P = .059).
- 益生菌显著改善了肠道通透性和炎症 (松素,α-1抗素) 的标志物,并减少了男性参与者的消化不良投诉.
结论:
- 益生菌补充剂对肠道健康标志物有显著的益处,并且在BD和SSD患者中安全且耐受良好.
- 对口头记忆的潜在边缘效应表明需要进一步调查.
- 针对微生物组的干预措施对管理复杂的大脑疾病具有前景,需要进一步研究.
相关概念视频
01:30Bipolar Disorder
56
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
56
01:23Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
01:21Drugs for Treatment of Constipation-Predominant IBS
137
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
137
01:17Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149